Published Date : Oct 2023
Category : Cardiovascular Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Adopting Healthy Environment: Analysing Innovations in Arrhythmias Domain

"Analysing new developments in Diagnostic and Treatment of Arrhythmia: Bringing Health Benefits and Creating Stable Business"

An arrhythmia, or irregular heartbeat, is an issue with the heart's pace or rhythm. The heart beats too fast, too slowly, or in an irregular rhythm in arrhythmia. The most prevalent continuous heart arrhythmia affects both men and women and is one of the most common diseases of the cardiovascular system. Atrial fibrillation is a significant risk factor for ischemic stroke, resulting in an extensive financial burden as well as morbidity and mortality.

However, arrhythmias affect between 1.5% and 5% of the population stated by Cleveland Clinic. The common symptoms of arrhythmias are irregular heartbeat, lightheadedness, sweating, anxiety, syncope, dizziness, extreme fatigue, chest pain, and shortness of breath.

Arrhythmia causes the heartbeat to increase or slow irregularly. Bradycardia is a resting state of the heart in which heartbeats slow down to 60 beats per minute. However, tachycardia causes a fast heartbeat up to 100 beats per minute. An early heartbeat or extra heartbeat is caused by due signal that the heart beating comes early.

The arrhythmia is caused by various factors that include coronary artery disease, irritable tissue in the heart, high BP, cardiomyopathy, electrolyte imbalancement, injury due to heart attack, healing of tissue post-surgery, and other medical conditions. 

However, arrhythmia is divided into various types and subtypes. Supraventricular arrhythmias, atrial fibrillation, and ventricular arrhythmias are the main types of arrhythmias. Ventricular tachycardia is characterized by rapid, regular beating of the ventricles that lasts only a few seconds or much more. Ventricular fibrillation occurs when electrical impulses cause the ventricles to contract rather than pump regularly.

The most prevalent kind of arrhythmia is atrial fibrillation. Atrial fibrillation has affected more than 2.5 million people in the United States. Because of this ailment, the heart beats at a rate of more than 400 beats per minute. Atrial fibrillation appeared on 183,321 death certificates in 2019 and was the reason for death in 26,535 of those cases as stated by the CDC.

Moreover, the upper chambers of the heart pulse 250–350 times per minute as a result of atrial flutter. Scarred or injured tissue may obstruct the signal that instructs the atria to beat. In Paroxysmal Supraventricular Tachycardia (PSVT) extra heartbeats are caused by a problem with the electrical signals that begin in the upper chambers and flow to the lower chambers. This form of arrhythmia starts and stops suddenly.

Furthermore, there are various risk factors associated with arrhythmias. Some of them include age, high blood pressure, obesity, ancestors of European origin, diabetes, heart attack, ischemia of the heart, hyperthyroidism, smoking, kidney disorders, and alcohol consumption.

The market for arrhythmias is influenced by various factors that include high prevalence rate, and increased hospitalizations worldwide. The other factors such as difficulties in determining the cause of disease occurrence all are helping to expand the business globally.

As a result of the arrhythmias outbreak, the number of patients is increasing which is why there is a need for the development of therapeutic products in the market. Supply and demand for such products are increasing which leads to the growth of the market worldwide.

DiseaseLandscape Insights helps in making informed choices in the domain of medical technology, treatments, and diagnostics where different technologies and remarkable innovations will transform the landscape leading to tremendous growth.

Arrhythmias Diagnostic Analysis

“Keeping the Healthy Heartbeat: Detecting the Disease before It Obscures”.

Elevate the diagnostic offerings to new heights with the extensive DiseaseLandscape Insight services about the diagnostic analysis of arrhythmias disease empowers to deliver precision and excellence to the customers.

However, in the United States, approximately more than 454,000 hospitalizations with atrial fibrillation diagnoses are reported every year.

The below tests are performed to diagnose the arrhythmias:

  • Blood Tests

Blood tests are the basic and initial tests used to diagnose arrhythmias. This test is performed to measure the level of electrolytes like sodium, potassium, etc. Also, the amount of thyroid hormone is checked during the blood analysis.

  • Electrocardiogram

The most frequent test for identifying arrhythmias is an electrocardiogram (EKG or ECG). An EKG quantifies the electrical activity of the heart. During a stress test, the doctor does an EKG, which monitors the heart's activity when it is working hard and pumping quickly. Arrhythmia detection accuracy for ventricular segments is 99.1% and 99.8% in the atrial segments.

  • Genetic Tests

Genetic testing determines whether a patient has a type of arrhythmia caused by a certain gene. This test is relevant if one or more of the patient's close relatives has an arrhythmia caused by the same gene or has suffered a cardiac arrest.

  • Heart Imaging Tests

Heart imaging tests, such as computed tomography (CT) scan or cardiac magnetic resonance imaging (MRI), examine the anatomy of the heart chambers, demonstrate how well the heart functions, search for indications of scar tissue in the heart muscle, and occasionally examine heart arteries.

DiseaseLandscape Insights assists key players by providing knowledge about diagnostic kits, the use of new technology for improving the existing as well as new diagnostic tools, and the data of current industry players and their innovative products for a better understanding of the market dynamics. Stakeholders should determine their plan of action and strategies for their business and ways for expanding the market by using DLI data.

The following table lists the names of the market leaders who are redefining healthcare with their forefront diagnostic innovations:

                                                                            Diagnostic Market Player

Blood Test


Genetic Tests

Heart Imaging Tests

Apollo Diagnostics

Cadwell Industries Inc.


GE Healthcare

Cipla Limited



Hitachi Ltd.

Dr. Reddy’s Laboratory

Nexus Health Care


Med Imaging Solutions

Fortis Healthcare

Electrotech Medi Systems


Siemens Healthineers

Metropolis Healthcare Ltd.

Human-Device Interaction Lab

Bio – Rad laboratories

Radiance Imaging System

Sun Pharmaceuticals Industries Ltd.

Allengers Global Healthcare Private Limited


DiagnoTech Corporation



Elitech Group

Johnson & Johnson


                                                                                  Diagnostic Product Name

Blood Tests


Genetic Tests

Heart Imaging Tests

Roche cobas®

Wave Plus

AncestryDNA kit

HeartMate 3

Abbott Architect®

Electromyography (EMG) plus Inertial Measurement Unit (IMU) Sensor System

Therascreen BRAF V600E RGQ PCR Kit

CoreValve transcatheter heart valve

Isoton III®


Epi ProColon®








Eonis SCID-SMA Kit

Sapien 3

Latron® Primer


Praxis Extended RAS Panel



Arrhythmias Treatment Analysis

“Healing Arrhythmias with Innovative Therapies: Enhancing Public Health”

  • Medications

A slow, rapid, or irregular heartbeat is treated with one or more medications. Occasionally, medications are used with other forms of therapy. Arrhythmia medications worsen an arrhythmia if the dose is too high. Women experience this more frequently than males.

A medication used to treat low heartbeat is Atropine. Atropine is given to patients only during emergency medical services in the emergency ward. One of the side effects of Atropine is difficulty in swallowing. 

However, there are several medications used to treat fast heartbeat. Calcium channel blockers help to block the movements of calcium ions into the heart and blood vessels to decrease the heartbeat. However, by inhibiting the effects of adrenalin, beta blockers reduce heart rate and cardiac output and help in lowering blood pressure. The side effects of beta blockers are fatigue, stomach or sleep problems, and sexual dysfunction.

Moreover, potassium and sodium channel blockers are also used to treat arrhythmias. This blocker blocks the entry of ions like sodium and potassium and reduces blood pressure. Also, adenosine is another medication option available in the market. Adenosine shows adverse effects like chest pain, flushing, and shortness of breath.

  • Cardioversion

Cardioversion also called Defibrillation is a treatment that involves the use of external electric shocks to restore normal cardiac rhythm. When irregular heartbeats in the lower chambers of the heart, and the ventricles, threaten or cause cardiac arrest, cardioversion is performed in an emergency to avert death.

  • Catheter Ablation

Catheter ablation is a technique that prevents faulty electrical signals from entering the heart and producing an irregular heartbeat. Ablation is performed through a process known as cardiac catheterization, which involves passing flexible tubes, or catheters, into blood arteries until they reach the heart.

Catheter ablation has some risk factors during the procedure and at the time of recovery. Bleeding, infections, damage to blood vessels, heart damage, and blood clots. There is also a slight risk of developing cancer from radiation of the catheter ablation.

  • Pacemakers

A pacemaker is a little equipment that emits electrical pulses to aid in regular heartbeat. Pacemakers also assist the heart's chambers in synchrony so that they pump blood to your body more effectively.

The development of combined drugs with efficacy, the use of technology to develop novel procedures and equipment, and the launching of cost-effective therapies to treat arrhythmias are essential. Key players have tremendous scope in the mentioned treatment category of arrhythmias.

Industry players should use the research and consulting services of DiseaseLandscape Insights to enhance and evolve in the treatment sector of arrhythmias. DLI offers data about the treatment market players, their strategies, their innovative products, and market analysis to keep our clients updated and ahead of the competition. DLI also provides knowledge about current clinical trials of new drug development to promote the client for performing concentrated research and establishing a stable business.

The table below demonstrates the industry leaders who are revolutionizing the landscape and driving innovation in the search for better health outcomes, as well as the names of their products for the treatment of arrhythmias:

Treatment Market Player

Product Name

GlaxoSmithKline Pharmaceuticals Ltd.

Digoxin (Lanoxin)

ICI India Ltd.


Samarth Pharma Pvt. Ltd.

Propranolol (Samarth)


Amlodipine (Norvasc)


Nifedipine (Procardia)

Covis Pharma

Nisoldipine (Sular)

Nivagen Pharmaceuticals, Inc.

Verapamil (Verelan)


Disopyramide (Rhythmodan)

Teva Pharmaceuticals

Mixelitine (Teva-Mixelitine)

Upsher-Smith Laboratories, LLC.

Propafenone (Rythmol)


Dronedarone (Multaq)


Sotalol (Pro-Sotalol, PMS-Sotalol)


Regulatory Framework for Arrhythmias

“Understanding Regulatory Rules: Deciding Best Route for Business”

Arrhythmia's regulatory requirements from various countries are sorted by DiseaseLandscape Insights. DLI provides empirical data on risk monitoring, risk assessment, and compliance with laws and regulations. By reviewing the DiseaseLandscape Insights services, businesses and other market stakeholders avoid, manage, and respond to arrhythmia breakouts while ensuring the safety of those who are infected.

However, to promote the health of patients, Aveir Leadless Pacemaker was authorized by the FDA on March 31, 2022, for use in patients with slow or irregular heart rhythms who benefit from a pacemaker system that functions in one chamber of the heart.

Ongoing regulatory permissions promote market expansion. For instance, in 2022, the FDA approved artificial intelligence and machine learning medical device trials to enhance the sensitivity and accuracy of devices and the disease diagnosis outcome. The diagnosis of arrhythmia with imaging tests is now fast and accurate.

Competitive Analysis

“Decoding the Competitive Landscape for Adopting Strategies”

A number of international industries are concentrating on the discovery, development, and launching of novel products and increasing the use of technology to improve existing processes in order to increase their competitive edge. Organizations are also focusing on ways to expand their product offerings, most commonly through acquisition alliances, regulatory approval for medical research, and an emphasis on cooperation.

However, the companies like, Abbott received extended authorization for its CardioMEMS HF System, a wireless device that detects and monitors pulmonary artery (PA) pressure and heart rate in patients with heart failure (HF) and arrhythmia. The development of this product has increased the overall revenue of Abbott Company. Many other companies have collaborated with Abbott due to innovations in the pacemakers industry.

Market Trends

“Evaluating the New Developments in Market to Expand the Business”

The market for arrhythmia is growing continuously due to the need for the development of cost-effective and accurate diagnostic kits. Innovations in medication discovery, formulations of medicines, and finding new therapies and procedures are also required to promote patient health.

However, with the advancement in Artificial Intelligence (AI) technology, several machine learning techniques are used in ECG signal feature identification which helps to solve problems related to huge amounts of ECG signal features and a heavy load of manual identification. Innovations and developments in this area are essential. Key players have tremendous opportunities in this domain to grow continuously.

Moreover, FDA-approved medical devices, there has been a surge of direct-to-consumer handheld or portable monitors (i.e., watches), mobile phone adaptors, and smartphone applications that allow patients to track their heart rhythm, as well as other biological parameters such as blood pressure, glucose, and so on. Launching of portable, cheap, and easy-handling devices is the area where huge business is established. New and existing industry player have scope in this field to expand their businesses globally.

Scientists are also working on imaging, body surface recordings, and radiation treatment advancements in combination to enable noninvasive ablation of arrhythmogenic substrates by stereotactic application of external beam radiation or focused ultrasound. The key player should enter into the research and developments of imaging and other therapy sectors to enhance their growth and increase their portfolio.

Clinical Trial Assessment

The advancement in technology research and government initiatives has increased the scope for clinical trials. One of the main objectives of healthcare reform is realized by industry participants thoroughly assessing medical therapy using clinical data.

DiseaseLandscape Insights helps in the design and management of clinical trials for novel medications and therapies, patient recruiting plans, regulatory compliance, and the protection of successful trial outcomes, etc.

The below table enlists study titles of clinical trials currently in development according to the phases they are being conducted:

Phase I

Phase II

Phase III

Phase IV

Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart Failure

Cardiac Arrhythmia Catheter Ablation Procedures Guided by X-ray Imaging: N-Acetylcysteine Protection Against Radiation-Induced Cellular damagE (CARAPACE Study)

The TIGHT-K STUDY. Prevention of Dysrhythmias in the Cardiac Intensive Care Unit - Does Maintenance of High-normal Serum Potassium Levels Matter

Efficacy of Dexmedetomidine and Magnesium Sulfate in Preventing Postoperative Junctional Ectopic Tachycardia After Pediatric Cardiac Surgery: Randomized Controlled Trial

Cardioprotection of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Angioplasty Through a Combined Antioxidant Therapy. A Phase I, Randomized Clinical Trial.

A Randomized Controlled Trial of RyR2 Inhibition With Dantrolene and Susceptibility to Ventricular Arrhythmias in Patients With Structural Heart Disease.

Randomized Controlled Trial of Magnesium Sulfate Versus Placebo on the Prevention of Atrial Fibrillation Post Cardiac Surgery.

Effect of EMPAgliflozin on The HeterogeneitY of Ventricular Repolarization in Patients With Diabetes and Coronary HEART Disease.

Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control

Randomized Controlled Trial of Magnesium Sulfate Versus Placebo on the Prevention of Atrial Fibrillation Post Cardiac Surgery.

PLAI-AF Trial: Hybrid Endo-epicardial Partial Left Atrial Isolation vs. Endocardial Ablation in Patients With Persistent Atrial Fibrillation

Arrhythmia Prevention in High Risk Cardiovascular Patients Using Targeted Potassium Levels

The Effect of Intra Operative Dexmedetomidine in Prevention of Early Postoperative Atrial Fibrillation in Patients Undergoing Thoracic Non Cardiac Surgeries: a Randomized Controlled Trial

Adjunctive GP Ablation In Redo-PVI: Paroxysmal Atrial Arrhythmias After Pulmonary Vein Isolation Are Driven By Ectopy-Triggering Left Atrial Ganglionated Plexus

REACT-AF: Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

The Leadless AV Versus DDD Pacing Study: A Randomized Controlled Single-center Trial on Leadless Versus Conventional Cardiac Dual-chamber Pacing

Synaptic Plasticity in the Epicardial Ganglionated Plexi

Evaluation of PET/MR in Patients Selected for Ablation Therapy

Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: A Randomized Digoxin Versus Beta Blocker Study

Safety Assessment for Sotalol Protocol in Outpatient Unit

Pilot-Tart Cherry, Mitral Transcriptome, and POAF Incidence

Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1)

Preventive VT Substrate Ablation in Patients With Chronic Post-MI Scar Showing Arrhythmogenic Characteristics

Prophylactic Intra-Operative Ventricular Arrhythmia Ablation in High-Risk LVAD Candidates (PIVATAL)



There are different market scenarios concerning countries/regions for arrhythmia-specific diagnostics and therapies. Because of the impact of arrhythmia and difficulties related to the economic viability of treating arrhythmia, governments have shown various investments and centers development in the arrhythmia diagnosis and treatment field.

DLI aids in identifying the target market, driving marketing strategies, and keeping industry participants informed of emerging trends. With the utilization of DLI expertise, healthcare organizations attain a competitive edge, optimize patient outcomes, and actively contribute to the advancement of global healthcare standards.

This encourages global companies to perform research on the treatment and diagnostic field of arrhythmia and understand manufacturers, legal compliance. All in all, DiseaseLandscape Insights helps all the market players to establish a stronger foothold.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape